JAZZ - Jazz to start clinical trial for tumor candidate after FDA nod

Jazz Pharmaceuticals (NASDAQ:JAZZ) is set to initiate a clinical trial for pan-RAF inhibitor JZP815 developed by its partner Redx after the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application, the companies announced on Wednesday. The agency has greenlighted the IND application for JZP815 as a treatment for solid tumors and hematologic malignancies that contain mutations in the MAPK pathway. The IND clearance has triggered a milestone payment of $5M payable from Jazz (JAZZ) to the U.K.-based Redx. The initiation of the Phase 1 trial will mark the fifth candidate developed by Redx to enter the clinic. Redx has so far received $6.5M from a collaboration under which Jazz (JAZZ) agreed to acquire its pan-RAF inhibitor program in 2019.

For further details see:

Jazz to start clinical trial for tumor candidate after FDA nod